Nkarta (NKTX) Expected to Announce Earnings on Tuesday

Key Points

• Nkarta is set to announce its Q2 2025 earnings on August 12th, expecting a loss of ($0.37) per share, slightly improving from a previous loss of ($0.43) per share reported in May.
• The company's stock has declined by 2.6%, trading at $2.07, with increased institutional interest as several investors expanded their positions during the first quarter.
• Analyst sentiment remains mixed, with a consensus target price of $14.33 despite several recent reductions in price targets from various research firms.

Nkarta (NASDAQ:NKTX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Nkarta to post earnings of ($0.37) per share for the quarter.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nkarta Stock Performance

Nkarta stock traded down $0.03 during midday trading on Friday, hitting $1.98. 349,055 shares of the company's stock were exchanged, compared to its average volume of 583,655. Nkarta has a 12-month low of $1.31 and a 12-month high of $6.63. The stock has a market cap of $140.50 million, a price-to-earnings ratio of -1.31 and a beta of 0.72. The firm's 50 day simple moving average is $1.90 and its 200 day simple moving average is $1.90.

Wall Street Analysts Forecast Growth

NKTX has been the topic of several research reports. Mizuho lowered their price objective on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a research report on Tuesday, June 10th. Needham & Company LLC reduced their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Finally, William Blair reiterated a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $14.33.

Institutional Trading of Nkarta

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. grew its position in shares of Nkarta by 478.4% during the first quarter. Invesco Ltd. now owns 69,396 shares of the company's stock worth $128,000 after acquiring an additional 57,399 shares during the last quarter. Jane Street Group LLC grew its position in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock worth $247,000 after acquiring an additional 852,559 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Nkarta by 300.5% during the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock worth $1,237,000 after acquiring an additional 504,272 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company's stock worth $1,253,000 after acquiring an additional 80,211 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Nkarta by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company's stock worth $2,006,000 after acquiring an additional 10,065 shares during the last quarter. Institutional investors own 80.54% of the company's stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.